Track market-moving stories before they get noisy

IQVIA Holdings (IQV - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on October 27, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis clinical testing company is expected to post quarterly earnings of $3.24 per share in its upcoming report, which represents a year-over-year change of +8%.

Revenues are expected to be $4.36 billion, up 6.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for IQVIA?For IQVIA, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.09%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that IQVIA will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that IQVIA would post earnings of $3.02 per share when it actually produced earnings of $3.15, delivering a surprise of +4.30%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

IQVIA doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Maia Wealth LLC trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 44.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,678 shares of the medical research company’s stock after selling 2,886 shares during the quarter. Maia Wealth LLC’s holdings in IQVIA were worth $989,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sterling Investment Counsel LLC increased its stake in shares of IQVIA by 2.2% in the third quarter. Sterling Investment Counsel LLC now owns 3,847 shares of the medical research company’s stock valued at $1,034,000 after buying an additional 82 shares during the period. Vontobel Holding Ltd. raised its holdings in IQVIA by 12.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 282,916 shares of the medical research company’s stock valued at $76,062,000 after buying an additional 30,348 shares during the last quarter. Cyndeo Wealth Partners LLC acquired a new stake in IQVIA during the 3rd quarter worth approximately $315,000. Hanson & Doremus Investment Management boosted its position in IQVIA by 1.7% during the 3rd quarter. Hanson & Doremus Investment Management now owns 15,699 shares of the medical research company’s stock worth $4,221,000 after buying an additional 257 shares during the period. Finally, Pension & Wealth Management Advisors Inc. bought a new stake in IQVIA during the 3rd quarter worth approximately $30,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the transaction, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth Several brokerages have issued reports on IQV. Royal Bank Of Canada upped their price target on shares of IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a research report on Tuesday, September 29th. TD Cowen raised their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Mizuho lifted their price target on shares of IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, October 7th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Finally, Truist Financial reissued a “buy” rating and issued a $329.00 price objective (up from $300.00) on shares of IQVIA in a research note on Monday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $276.00. View Our Latest Report on IQV

IQVIA Trading Down 0.4% Shares of IQV stock opened at $265.72 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $277.40. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $43.74 billion, a price-to-earnings ratio of 32.97, a PEG ratio of 2.32 and a beta of 1.17. The stock has a 50-day moving average of $261.23 and a 200-day moving average of $213.85.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the firm earned $2.81 earnings per share. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.56 earnings per share for the current year.

IQVIA Company Profile (Free Report)

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.

Further Reading Five stocks we like better than IQVIA Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

RESEARCH TRIANGLE PARK, N.C. & PLEASANTON, Calif.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously announced EDC partnership. Together, IQVIA and Veeva bring best-in-class capabilities to clinical research to help customers increase tr.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA's proprietary expert content, deep domain knowledge and established regulatory, com.

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Colgate-Palmolive Company (NYSE:CL). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Colgate-Palmolive stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. Colgate-Palmolive Stock Performance NYSE:CL opened at $86.51 on Tuesday. The stock has a market cap of $68.96 billion, a P/E ratio of 34.33, a PEG ratio of 4.01 and a beta of 0.33. The company has a quick ratio of 0.67, a current ratio of 1.03 and a debt-to-equity ratio of 13.82. The business’s 50-day moving average price is $90.04 and its two-hundred day moving average price is $88.88. Colgate-Palmolive Company has a twelve month low of $74.54 and a twelve month high of $99.33.

Colgate-Palmolive (NYSE:CL – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $0.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.04. The business had revenue of $5.36 billion for the quarter, compared to the consensus estimate of $5.36 billion. Colgate-Palmolive had a net margin of 9.68% and a return on equity of 464.63%. Colgate-Palmolive’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. As a group, equities analysts predict that Colgate-Palmolive Company will post 3.87 EPS for the current fiscal year. Colgate-Palmolive Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Tuesday, October 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 84.13%.

Insider Activity In related news, Director John T. Cahill sold 4,170 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $93.37, for a total transaction of $389,352.90. Following the completion of the sale, the director directly owned 28,373 shares in the company, valued at $2,649,187.01. This represents a 12.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Panagiotis Tsourapas sold 10,000 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $92.05, for a total transaction of $920,500.00. Following the completion of the sale, the chief operating officer directly owned 64,901 shares in the company, valued at approximately $5,974,137.05. This trade represents a 13.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 175,191 shares of company stock valued at $16,110,903. 0.43% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades CL has been the subject of a number of research analyst reports. UBS Group lifted their price objective on shares of Colgate-Palmolive from $106.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada restated an “outperform” rating and set a $104.00 price target on shares of Colgate-Palmolive in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $101.00 price target on shares of Colgate-Palmolive in a research note on Monday, August 3rd. Wells Fargo & Company increased their price objective on Colgate-Palmolive from $92.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Finally, Piper Sandler decreased their price objective on Colgate-Palmolive from $98.00 to $95.00 and set an “overweight” rating on the stock in a report on Monday, September 21st. Thirteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Colgate-Palmolive currently has an average rating of “Moderate Buy” and a consensus target price of $98.94.

Read Our Latest Stock Analysis on Colgate-Palmolive

Institutional Trading of Colgate-Palmolive Several institutional investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. lifted its stake in shares of Colgate-Palmolive by 466.3% in the 2nd quarter. QRG Capital Management Inc. now owns 215,380 shares of the company’s stock valued at $19,746,000 after acquiring an additional 177,350 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in Colgate-Palmolive by 257.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 69,161 shares of the company’s stock worth $6,341,000 after acquiring an additional 49,803 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Colgate-Palmolive by 266.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,146,337 shares of the company’s stock worth $380,136,000 after purchasing an additional 3,014,860 shares during the period. Andra AP fonden purchased a new position in Colgate-Palmolive in the 2nd quarter worth approximately $18,214,000. Finally, State Street Corp lifted its position in Colgate-Palmolive by 97.4% in the second quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after purchasing an additional 46,476,510 shares during the last quarter. 80.41% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

(Get Free Report)

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwashes, body washes, deodorants, soaps, household cleaning products and pet food and treats.

The company markets many of its products under well-known brands, including Colgate, Palmolive, elmex, meridol, Protex, Softsoap, Ajax, Irish Spring, Speed Stick, Tom’s of Maine and Hill’s Science Diet.

Featured Articles Five stocks we like better than Colgate-Palmolive Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of The TJX Companies, Inc. (NYSE:TJX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in TJX Companies stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. TJX Companies Price Performance Shares of TJX Companies stock opened at $130.28 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.15 and a quick ratio of 0.56. The company has a market cap of $143.31 billion, a PE ratio of 24.08, a price-to-earnings-growth ratio of 2.34 and a beta of 0.60. The firm has a fifty day moving average price of $142.28 and a two-hundred day moving average price of $151.91. The TJX Companies, Inc. has a fifty-two week low of $122.78 and a fifty-two week high of $170.00.

TJX Companies (NYSE:TJX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 19th. The apparel and home fashions retailer reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.03. TJX Companies had a net margin of 9.73% and a return on equity of 56.56%. The company had revenue of $15.18 billion for the quarter, compared to the consensus estimate of $15.16 billion. During the same quarter in the previous year, the firm posted $1.10 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. TJX Companies has set its FY 2027 guidance at 5.150-5.200 EPS and its Q3 2027 guidance at 1.360-1.380 EPS. Analysts expect that The TJX Companies, Inc. will post 5.22 EPS for the current year. TJX Companies Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Thursday, November 12th will be paid a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 1.5%. The ex-dividend date is Thursday, November 12th. TJX Companies’s dividend payout ratio is presently 35.49%.

Analysts Set New Price Targets A number of analysts have commented on TJX shares. Evercore reiterated an “outperform” rating and issued a $173.00 price objective on shares of TJX Companies in a research report on Thursday, August 20th. Sanford C. Bernstein reiterated an “outperform” rating and set a $175.00 target price on shares of TJX Companies in a research report on Tuesday, August 25th. BTIG Research reissued a “buy” rating and issued a $190.00 price target on shares of TJX Companies in a research report on Thursday, August 20th. Morgan Stanley set a $178.00 price target on shares of TJX Companies and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Finally, Citigroup downgraded TJX Companies from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $182.00 to $154.00 in a report on Thursday, August 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, TJX Companies presently has an average rating of “Moderate Buy” and a consensus target price of $171.63.

View Our Latest Stock Analysis on TJX

Hedge Funds Weigh In On TJX Companies Several institutional investors have recently added to or reduced their stakes in TJX. Danske Bank A S acquired a new position in shares of TJX Companies in the 2nd quarter valued at $829,000. J.Safra Asset Management Corp lifted its stake in TJX Companies by 78.3% in the fourth quarter. J.Safra Asset Management Corp now owns 6,805 shares of the apparel and home fashions retailer’s stock valued at $1,045,000 after buying an additional 2,989 shares during the period. Bluedoor Private Wealth LLC bought a new position in TJX Companies during the fourth quarter worth about $2,559,000. Sigma Planning Corp grew its position in shares of TJX Companies by 82.0% during the 2nd quarter. Sigma Planning Corp now owns 20,903 shares of the apparel and home fashions retailer’s stock worth $3,167,000 after buying an additional 9,417 shares during the period. Finally, Man Group plc bought a new stake in shares of TJX Companies in the 2nd quarter valued at about $217,422,000. 91.09% of the stock is owned by institutional investors.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About TJX Companies (Get Free Report)

The TJX Companies, Inc is an off-price retailer that sells apparel, footwear, accessories, home furnishings and other merchandise at prices generally below those of traditional department and specialty stores. Its inventory typically includes branded, designer and name-brand products purchased through opportunistic buying, including order cancellations, excess production and closeout merchandise. Product selection and pricing can vary by store and change frequently.

The company operates a portfolio of retail chains in the United States, Canada, Europe and Australia.

Further Reading Five stocks we like better than TJX Companies Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for TJX Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TJX Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of CSX Corporation (NASDAQ:CSX). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in CSX stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. CSX Stock Down 0.0% Shares of NASDAQ CSX opened at $46.76 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 0.72 and a current ratio of 0.82. CSX Corporation has a 52 week low of $33.63 and a 52 week high of $53.60. The stock has a market capitalization of $86.62 billion, a P/E ratio of 27.03, a PEG ratio of 2.20 and a beta of 1.21. The stock’s fifty day moving average is $49.73 and its 200 day moving average is $46.57.

CSX (NASDAQ:CSX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The transportation company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.02. The company had revenue of $3.94 billion during the quarter, compared to the consensus estimate of $3.89 billion. CSX had a net margin of 22.21% and a return on equity of 24.98%. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.44 EPS. Sell-side analysts forecast that CSX Corporation will post 2 earnings per share for the current fiscal year. CSX Announces Dividend The business also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Investors of record on Monday, August 31st were given a $0.14 dividend. The ex-dividend date was Monday, August 31st. This represents a $0.56 dividend on an annualized basis and a dividend yield of 1.2%. CSX’s dividend payout ratio (DPR) is presently 32.37%.

Analysts Set New Price Targets A number of brokerages have weighed in on CSX. Citigroup raised their target price on CSX from $53.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Barclays restated an “overweight” rating and set a $60.00 price objective (up from $55.00) on shares of CSX in a research report on Thursday, July 23rd. Citizens Jmp started coverage on CSX in a research note on Wednesday, July 15th. They issued a “market perform” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $59.00 target price on shares of CSX in a research note on Friday, July 24th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $52.00 target price (up from $49.00) on shares of CSX in a report on Thursday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.24.

Get Our Latest Report on CSX

Insider Activity at CSX In other news, SVP Michael Burns sold 13,000 shares of the stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $52.68, for a total value of $684,840.00. Following the completion of the sale, the senior vice president directly owned 59,643 shares of the company’s stock, valued at $3,141,993.24. This represents a 17.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Angela Williams sold 30,000 shares of CSX stock in a transaction that occurred on Friday, July 24th. The shares were sold at an average price of $53.29, for a total value of $1,598,700.00. Following the transaction, the chief accounting officer directly owned 10,437 shares in the company, valued at approximately $556,187.73. The trade was a 74.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently made changes to their positions in CSX. Evolve Private Wealth LLC bought a new stake in shares of CSX during the second quarter worth about $693,000. M. Kulyk & Associates LLC bought a new position in CSX in the 2nd quarter valued at about $8,145,000. Wealthfront Advisers LLC bought a new position in CSX in the 2nd quarter valued at about $7,609,000. B. Metzler seel. Sohn & Co. AG acquired a new position in CSX during the 2nd quarter valued at about $6,598,000. Finally, First National Bank of Omaha bought a new stake in CSX during the 2nd quarter worth approximately $6,248,000. Institutional investors and hedge funds own 73.57% of the company’s stock.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About CSX (Get Free Report)

CSX Corporation (NASDAQ:CSX) is a transportation company that provides rail-based freight services through its principal subsidiary, CSX Transportation. The company moves a broad range of products, including agricultural and food products, chemicals, minerals, forest products, metals, automotive shipments, and consumer goods.

CSX also provides intermodal transportation, connecting rail shipments with trucks, ports, and distribution facilities. Its network serves the eastern United States and reaches parts of Canada, linking major industrial regions, population centers, manufacturing locations, and Atlantic and Gulf Coast ports.

CSX traces its history to the 1980 merger of Chessie System and Seaboard Coast Line Industries.

Recommended Stories Five stocks we like better than CSX Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for CSX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSX and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently bought shares of CocaCola Company (The) (NYSE:KO). In a filing disclosed on September 25th, the Representative disclosed that they had bought between $1,001 and $15,000 in CocaCola stock on August 31st. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. CocaCola Stock Down 0.6% KO opened at $87.25 on Tuesday. The business has a 50 day moving average price of $87.74 and a two-hundred day moving average price of $82.19. CocaCola Company has a 52 week low of $65.35 and a 52 week high of $92.49. The company has a market cap of $375.38 billion, a PE ratio of 26.20, a P/E/G ratio of 3.42 and a beta of 0.34. The company has a quick ratio of 1.12, a current ratio of 1.30 and a debt-to-equity ratio of 0.97.

CocaCola (NYSE:KO – Get Free Report) last released its earnings results on Tuesday, July 28th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. CocaCola had a return on equity of 39.38% and a net margin of 28.56%.The business had revenue of $13.37 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. CocaCola has set its FY 2026 guidance at 3.270-3.300 EPS. As a group, research analysts anticipate that CocaCola Company will post 3.29 EPS for the current year. CocaCola Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $2.12 annualized dividend and a yield of 2.4%. CocaCola’s dividend payout ratio is currently 63.66%.

Wall Street Analysts Forecast Growth A number of equities analysts have commented on KO shares. Seaport Research Partners set a $95.00 price objective on shares of CocaCola in a research report on Friday, August 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $100.00 price target (up from $89.00) on shares of CocaCola in a research note on Wednesday, July 29th. Daiwa Securities Group raised their price objective on shares of CocaCola from $83.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Barclays increased their price target on CocaCola from $91.00 to $93.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Weiss Ratings upgraded shares of CocaCola from a “buy (b+)” rating to a “buy (a-)” rating in a report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.18.

Read Our Latest Research Report on CocaCola

Insider Buying and Selling In other news, EVP Nancy Quan sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $90.39, for a total transaction of $4,519,500.00. Following the transaction, the executive vice president owned 223,330 shares in the company, valued at approximately $20,186,798.70. The trade was a 18.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman James Quincey sold 145,947 shares of CocaCola stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $90.09, for a total value of $13,148,365.23. Following the sale, the chairman directly owned 122,833 shares in the company, valued at approximately $11,066,024.97. This trade represents a 54.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 926,620 shares of company stock worth $83,075,714. 0.90% of the stock is currently owned by corporate insiders.

CocaCola News Roundup Here are the key news stories impacting CocaCola this week:

Positive Sentiment: JPMorgan Chase reaffirmed its Buy/Overweight view on Coca-Cola, indicating continued confidence in the company’s defensive earnings profile and long-term growth prospects. Positive Sentiment: Coca-Cola’s global beverage volume increased 5% year over year in the second quarter of fiscal 2026. Strong execution, product innovation, portfolio breadth and revenue-management initiatives are supporting demand across markets. What’s Driving Coca-Cola’s Broad-Based Global Volume Growth? Positive Sentiment: Coca-Cola continues to attract bullish Wall Street commentary, reinforcing investor interest in its consistent earnings, dividend growth and relatively defensive business model. Is It Worth Investing in Coca-Cola Based on Wall Street’s Bullish Views? Neutral Sentiment: Coca-Cola hired a senior executive from Monster Beverage. The appointment could support future innovation and growth, although its financial impact is not yet clear. Coca-Cola Hires a Key Executive From Monster Beverage Neutral Sentiment: Coca-Cola’s long record of consecutive dividend increases continues to make it attractive to income-focused investors, though dividend history alone may not drive an immediate price reaction. How Many Coca-Cola Shares Are Needed for $10,000 in Yearly Dividends? Negative Sentiment: JPMorgan reduced its price target from $96 to $95 while retaining an Overweight rating. The change still implies meaningful upside, but signals slightly less near-term appreciation potential. Negative Sentiment: One analysis cautioned that Coca-Cola’s strong rally, premium valuation and already-robust earnings and dividend record may leave less room for further gains, potentially contributing to recent weakness. Be Careful With Coca-Cola Right Now Institutional Trading of CocaCola Hedge funds and other institutional investors have recently bought and sold shares of the company. Eurizon SLJ Capital Ltd bought a new position in CocaCola in the 4th quarter worth approximately $552,000. Banco Santander S.A. grew its stake in shares of CocaCola by 3.1% in the second quarter. Banco Santander S.A. now owns 1,090,758 shares of the company’s stock worth $88,646,000 after acquiring an additional 32,723 shares during the last quarter. Daymark Wealth Partners LLC increased its position in CocaCola by 68.5% during the second quarter. Daymark Wealth Partners LLC now owns 218,199 shares of the company’s stock worth $17,733,000 after acquiring an additional 88,690 shares during the period. Cibc World Market Inc. raised its stake in CocaCola by 4.8% during the 4th quarter. Cibc World Market Inc. now owns 1,759,546 shares of the company’s stock valued at $123,010,000 after purchasing an additional 79,946 shares during the last quarter. Finally, Moore Capital Management LP acquired a new position in CocaCola during the 2nd quarter valued at $12,905,000. 70.26% of the stock is owned by institutional investors.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About CocaCola (Get Free Report)

The Coca-Cola Company (NYSE: KO) is a global beverage company headquartered in Atlanta, Georgia. Its portfolio includes sparkling soft drinks, water, sports drinks, coffee, tea, juice, dairy and plant-based beverages, and other ready-to-drink products. The company’s best-known brands include Coca-Cola, Diet Coke, Coca-Cola Zero Sugar, Sprite, Fanta, Dasani, Powerade, Minute Maid, fairlife, and Georgia Coffee.

Founded in 1886, the company develops, owns, licenses, markets, and distributes beverage brands through a network of bottling partners, distributors, retailers, and food-service operators.

Read More Five stocks we like better than CocaCola Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for CocaCola Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CocaCola and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Pembina Pipeline Corp. (NYSE:PBA). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Pembina Pipeline stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. Pembina Pipeline Price Performance NYSE PBA opened at $45.08 on Tuesday. The firm’s 50 day moving average is $48.39 and its 200-day moving average is $47.12. The company has a quick ratio of 0.50, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $26.22 billion, a PE ratio of 22.10 and a beta of 0.58. Pembina Pipeline Corp. has a 12-month low of $36.20 and a 12-month high of $51.58.

Pembina Pipeline (NYSE:PBA – Get Free Report) (TSE:PPL) last issued its quarterly earnings results on Thursday, July 30th. The pipeline company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.01). Pembina Pipeline had a net margin of 22.41% and a return on equity of 11.41%. The business had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the previous year, the firm posted $0.65 earnings per share. The firm’s quarterly revenue was up 20.1% on a year-over-year basis. Equities research analysts anticipate that Pembina Pipeline Corp. will post 2.2 earnings per share for the current fiscal year. Pembina Pipeline Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a C$0.73 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $2.94 dividend on an annualized basis and a dividend yield of 6.5%. Pembina Pipeline’s dividend payout ratio (DPR) is 103.92%.

Institutional Inflows and Outflows Large investors have recently bought and sold shares of the stock. Tidal Investments LLC boosted its holdings in shares of Pembina Pipeline by 5.8% during the second quarter. Tidal Investments LLC now owns 38,858 shares of the pipeline company’s stock worth $1,797,000 after acquiring an additional 2,145 shares during the period. M.E. Allison & CO. Inc. increased its stake in shares of Pembina Pipeline by 4.9% during the second quarter. M.E. Allison & CO. Inc. now owns 7,815 shares of the pipeline company’s stock worth $361,000 after purchasing an additional 365 shares during the period. Cidel Asset Management Inc. lifted its holdings in Pembina Pipeline by 22.0% during the 2nd quarter. Cidel Asset Management Inc. now owns 307,057 shares of the pipeline company’s stock worth $14,202,000 after purchasing an additional 55,401 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Pembina Pipeline in the 2nd quarter valued at $33,000. Finally, Baird Financial Group Inc. boosted its stake in Pembina Pipeline by 15.0% in the 2nd quarter. Baird Financial Group Inc. now owns 61,030 shares of the pipeline company’s stock valued at $2,823,000 after purchasing an additional 7,948 shares during the period. 55.37% of the stock is owned by institutional investors.

Analyst Ratings Changes A number of brokerages have recently issued reports on PBA. TD Securities reiterated a “buy” rating on shares of Pembina Pipeline in a research note on Thursday, July 16th. Canadian Imperial Bank of Commerce reiterated an “outperform” rating on shares of Pembina Pipeline in a research note on Friday, July 3rd. Scotiabank cut shares of Pembina Pipeline from a “sector outperform” rating to a “sector perform” rating in a report on Monday, July 20th. BMO Capital Markets reiterated a “market perform” rating on shares of Pembina Pipeline in a report on Friday, July 31st. Finally, Weiss Ratings lowered Pembina Pipeline from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, September 18th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.00.

Get Our Latest Report on Pembina Pipeline

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Pembina Pipeline Company Profile (Get Free Report)

Pembina Pipeline Corporation is a Canadian energy transportation and midstream services company headquartered in Calgary, Alberta. Founded in 1954, the company develops and operates infrastructure that transports and processes hydrocarbons produced primarily in Western Canada.

Pembina’s operations include conventional and oil sands pipelines, natural gas gathering and processing facilities, fractionation and storage assets, and terminals for hydrocarbon liquids. Its infrastructure supports the movement of crude oil, condensate, natural gas, propane, butane and other natural gas liquids from producing regions to domestic and international markets.

The company also provides marketing, logistics and related midstream services and is pursuing opportunities tied to liquefied natural gas and other energy exports.

Featured Stories Five stocks we like better than Pembina Pipeline Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for Pembina Pipeline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pembina Pipeline and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Devon Energy Corporation (NYSE:DVN). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Devon Energy stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. Devon Energy Stock Performance Shares of Devon Energy stock opened at $46.70 on Tuesday. The company has a current ratio of 0.72, a quick ratio of 0.67 and a debt-to-equity ratio of 0.24. The stock’s fifty day moving average price is $46.83 and its 200-day moving average price is $46.31. The firm has a market cap of $51.38 billion, a P/E ratio of 11.09, a P/E/G ratio of 1.27 and a beta of 0.37. Devon Energy Corporation has a 12 month low of $31.47 and a 12 month high of $52.71.

Devon Energy (NYSE:DVN – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The energy company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.17. The company had revenue of $7.42 billion during the quarter, compared to analyst estimates of $6.01 billion. Devon Energy had a net margin of 16.67% and a return on equity of 14.93%. The firm’s revenue for the quarter was up 73.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.84 earnings per share. On average, equities research analysts expect that Devon Energy Corporation will post 5.27 earnings per share for the current fiscal year. Devon Energy Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.32 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.28 annualized dividend and a dividend yield of 2.7%. Devon Energy’s dividend payout ratio (DPR) is currently 30.40%.

More Devon Energy News Here are the key news stories impacting Devon Energy this week:

Positive Sentiment: Wells Fargo maintained its overweight rating on Devon Energy, indicating continued confidence in the company’s earnings outlook and valuation. The bank’s revised $64 price target still implies substantial upside from recent trading levels, despite being reduced modestly from $65. Wells Fargo Remains a Buy on Devon Energy Positive Sentiment: Devon’s multi-basin footprint remains a key investment argument. Its exposure across several U.S. oil and gas regions, including the Eagle Ford, provides operational diversification and multiple avenues for production, cash flow and portfolio optimization. What Is Behind Devon Energy’s Multi-Basin Footprint? Neutral Sentiment: Devon is receiving elevated retail and market attention, with Zacks users actively evaluating whether the shares remain attractive. The coverage highlights valuation and fundamentals but does not represent a new company-specific catalyst. Is Trending Stock Devon Energy a Buy Now? Negative Sentiment: BP reportedly studied buying Devon’s Eagle Ford assets but ultimately walked away. The abandoned potential transaction removes a possible source of near-term asset-sale proceeds or takeover speculation, although it may also underscore the strategic value of Devon’s South Texas operations. BP vs. Devon: A Shale Deal That Never Happened Negative Sentiment: Wells Fargo’s reduction of its price target from $65 to $64 is a modest negative signal, suggesting slightly less upside in its updated assumptions. However, the continued overweight rating tempers the impact of the cut. Devon Energy Stock Price Target Lowered at Wells Fargo Insider Buying and Selling at Devon Energy In other Devon Energy news, EVP Robert Ferrall Lowe III sold 6,756 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $50.95, for a total value of $344,218.20. Following the sale, the executive vice president directly owned 72,720 shares of the company’s stock, valued at approximately $3,705,084. This represents a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Clay M. Gaspar purchased 3,913 shares of the business’s stock in a transaction on Monday, September 14th. The shares were bought at an average cost of $51.08 per share, for a total transaction of $199,876.04. Following the completion of the transaction, the chief executive officer directly owned 619,152 shares in the company, valued at $31,626,284.16. This trade represents a 0.64% increase in their position. The disclosure for this purchase is available in the SEC filing. 4.58% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on DVN. Wolfe Research set a $67.00 price target on shares of Devon Energy and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Barclays reduced their price objective on shares of Devon Energy from $62.00 to $58.00 and set an “overweight” rating for the company in a research note on Monday, August 17th. Wells Fargo & Company lowered their target price on Devon Energy from $65.00 to $64.00 and set an “overweight” rating for the company in a report on Monday. Seaport Research Partners initiated coverage on Devon Energy in a research report on Thursday, September 3rd. They set a “buy” rating and a $65.00 target price on the stock. Finally, Evercore upgraded Devon Energy from an “in-line” rating to an “outperform” rating and set a $54.00 price target on the stock in a report on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $59.72.

View Our Latest Analysis on DVN

Institutional Inflows and Outflows Hedge funds have recently modified their holdings of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Devon Energy during the fourth quarter worth about $25,000. Premier Financial Group acquired a new position in Devon Energy in the 2nd quarter worth approximately $25,000. JFS Wealth Advisors LLC raised its position in Devon Energy by 56.6% during the 2nd quarter. JFS Wealth Advisors LLC now owns 678 shares of the energy company’s stock worth $28,000 after buying an additional 245 shares during the last quarter. Parvin Asset Management LLC acquired a new stake in Devon Energy during the 2nd quarter valued at approximately $28,000. Finally, MV Capital Management Inc. acquired a new stake in Devon Energy during the 4th quarter valued at approximately $29,000. 69.72% of the stock is owned by institutional investors and hedge funds.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Devon Energy Company Profile (Get Free Report)

Devon Energy Corporation (NYSE: DVN) is an independent energy company engaged primarily in the exploration, development and production of oil, natural gas and natural gas liquids. The company operates in the United States and focuses on onshore properties with oil- and liquids-rich resources.

Devon’s operations are concentrated in several major U.S. producing regions, including the Delaware Basin in the Permian Basin, the Eagle Ford, the Anadarko Basin, the Williston Basin and the Powder River Basin.

See Also Five stocks we like better than Devon Energy Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for Devon Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devon Energy and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Walmart Inc. (NASDAQ:WMT). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Walmart stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. Walmart Trading Up 0.7% NASDAQ WMT opened at $108.73 on Tuesday. Walmart Inc. has a 52 week low of $98.88 and a 52 week high of $135.15. The firm has a 50 day moving average of $109.17 and a two-hundred day moving average of $117.47. The company has a quick ratio of 0.23, a current ratio of 0.77 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $862.64 billion, a PE ratio of 39.25, a price-to-earnings-growth ratio of 4.12 and a beta of 0.59.

Walmart (NASDAQ:WMT – Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The retailer reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. The business had revenue of $187.94 billion for the quarter, compared to analyst estimates of $186.64 billion. Walmart had a net margin of 3.00% and a return on equity of 21.83%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.68 EPS. Walmart has set its Q3 2027 guidance at 0.620-0.640 EPS and its FY 2027 guidance at 2.800-2.870 EPS. As a group, research analysts expect that Walmart Inc. will post 2.87 EPS for the current fiscal year. More Walmart News Here are the key news stories impacting Walmart this week:

Positive Sentiment: Membership revenue is emerging as a potential profit engine. Record fee revenue from Walmart+, Sam’s Club and international memberships is deepening customer engagement and could improve e-commerce economics through recurring, higher-margin income. Walmart’s Membership Gains Scale: Is It the Next Major Profit Engine? Positive Sentiment: Digital transformation is supporting the long-term earnings outlook. Analysts point to Walmart’s AI-enabled platform overhaul, expanding digital scale and potential for higher-margin growth as reasons for continued optimism. Is Walmart’s Digital Transformation Paying Off? Positive Sentiment: Walmart is expanding its store and transaction ecosystem. Continued rollout of the Neighborhood Market format and Google’s test of direct purchases from Walmart-owned Flipkart through Gemini and AI Mode could broaden customer reach and create additional digital-commerce channels. Walmart continues to expand its Neighborhood Market concept Neutral Sentiment: Leadership continuity may limit near-term uncertainty. John Furner’s appointment as CEO represents a new leadership chapter, while expanded debt-free employee training supports talent development and operational execution. The articles did not identify a major change to Walmart’s financial outlook. Walmart Names John Furner As CEO Neutral Sentiment: Walmart’s pricing pledge could reinforce customer trust. CEO John Furner’s statement that Walmart prices products rather than individuals addresses concerns about personalized pricing, though it is primarily a reputational and policy development rather than a direct earnings catalyst. Walmart’s CEO Ruled Out Personalized Pricing Negative Sentiment: Consumer and competitive risks remain. Lower U.S. consumer confidence could pressure discretionary spending, while Walmart’s push into beauty, health and wellness places it in more direct competition with specialized retailers such as Ulta Beauty. Is the Beauty Aisle Becoming Retail’s Next Big Battleground? Hedge Funds Weigh In On Walmart Institutional investors have recently modified their holdings of the business. State Street Corp increased its position in Walmart by 1.1% in the 2nd quarter. State Street Corp now owns 188,036,646 shares of the retailer’s stock valued at $21,297,031,000 after acquiring an additional 2,107,781 shares during the period. Geode Capital Management LLC increased its holdings in shares of Walmart by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 103,010,709 shares of the retailer’s stock valued at $11,426,753,000 after purchasing an additional 6,517,394 shares during the period. Bank of America Corp DE purchased a new stake in shares of Walmart during the second quarter worth approximately $7,455,131,000. Norges Bank acquired a new stake in shares of Walmart during the fourth quarter worth $6,458,529,000. Finally, Franklin Resources Inc. increased its stake in Walmart by 2.6% in the 4th quarter. Franklin Resources Inc. now owns 36,820,550 shares of the retailer’s stock valued at $4,102,546,000 after buying an additional 920,969 shares during the period. 26.76% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades Several equities research analysts have recently weighed in on WMT shares. Mizuho set a $130.00 target price on Walmart in a research report on Monday, July 27th. TD Cowen reiterated a “buy” rating on shares of Walmart in a research note on Friday, August 21st. BTIG Research reissued a “buy” rating and set a $140.00 price objective on shares of Walmart in a report on Thursday, September 10th. Cantor Fitzgerald upgraded shares of Walmart to a “buy” rating in a research report on Friday, August 21st. Finally, Citigroup lowered their target price on shares of Walmart from $147.00 to $132.00 and set a “buy” rating for the company in a report on Friday, August 21st. Three analysts have rated the stock with a Strong Buy rating, thirty-two have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $131.88.

Check Out Our Latest Stock Analysis on WMT

Insider Activity In other news, EVP Daniel Danker sold 50,644 shares of Walmart stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $105.35, for a total value of $5,335,345.40. Following the sale, the executive vice president owned 201,672 shares of the company’s stock, valued at $21,246,145.20. The trade was a 20.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Christopher Nicholas sold 2,900 shares of the stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $106.65, for a total transaction of $309,285.00. Following the transaction, the executive vice president directly owned 566,253 shares of the company’s stock, valued at $60,390,882.45. This represents a 0.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 81,004 shares of company stock worth $8,601,724 over the last quarter. Insiders own 0.09% of the company’s stock.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Walmart (Get Free Report)

Walmart Inc (NASDAQ: WMT) is a multinational retailer that operates supercenters, discount stores, neighborhood markets, warehouse clubs and e-commerce platforms. Its merchandise includes groceries, apparel, electronics, home goods, health and wellness products, household essentials and general merchandise. Walmart also provides services such as grocery pickup and delivery, pharmacy services, financial products and digital advertising.

The company serves customers through its Walmart U.S., Walmart International and Sam’s Club segments.

See Also Five stocks we like better than Walmart Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for Walmart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walmart and related companies with MarketBeat.com's FREE daily email newsletter.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Honeywell International Inc. (NASDAQ:HON). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Honeywell International stock on August 31st. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026. Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026. Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026. Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026. Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026. Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026. Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026. Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026. Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026. Honeywell International Trading Down 0.5% Shares of Honeywell International stock opened at $211.52 on Tuesday. The stock has a 50 day moving average of $222.93 and a 200 day moving average of $224.08. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.93 and a current ratio of 1.21. The firm has a market capitalization of $67.04 billion, a price-to-earnings ratio of 8.18, a PEG ratio of 3.56 and a beta of 0.87. Honeywell International Inc. has a fifty-two week low of $196.59 and a fifty-two week high of $261.24.

Honeywell International (NASDAQ:HON – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The conglomerate reported $1.95 EPS for the quarter, beating the consensus estimate of $1.80 by $0.15. The business had revenue of $9.72 billion for the quarter, compared to analyst estimates of $5.03 billion. Honeywell International had a return on equity of 34.00% and a net margin of 23.90%.The company’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.77 EPS. Honeywell International has set its Q3 2026 guidance at 2.050-2.200 EPS and its Q4 2026 guidance at 2.280-2.430 EPS. As a group, research analysts predict that Honeywell International Inc. will post 8.29 earnings per share for the current year. Honeywell International Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 4th. Investors of record on Friday, November 13th will be given a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.3%. The ex-dividend date is Friday, November 13th. Honeywell International’s dividend payout ratio is presently 36.80%.

Hedge Funds Weigh In On Honeywell International Several hedge funds and other institutional investors have recently added to or reduced their stakes in HON. J. Stern & Co. LLP boosted its holdings in shares of Honeywell International by 22,704.6% during the fourth quarter. J. Stern & Co. LLP now owns 53,209,042 shares of the conglomerate’s stock worth $10,380,552,000 after purchasing an additional 52,975,716 shares during the last quarter. State Street Corp lifted its position in Honeywell International by 3.4% during the fourth quarter. State Street Corp now owns 31,677,082 shares of the conglomerate’s stock worth $6,179,882,000 after buying an additional 1,031,897 shares during the period. Geode Capital Management LLC boosted its stake in Honeywell International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 15,716,647 shares of the conglomerate’s stock worth $3,066,520,000 after buying an additional 120,929 shares during the last quarter. Bank of America Corp DE grew its holdings in Honeywell International by 0.3% in the 1st quarter. Bank of America Corp DE now owns 9,124,527 shares of the conglomerate’s stock valued at $2,062,417,000 after buying an additional 31,551 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Honeywell International by 0.3% in the 4th quarter. Franklin Resources Inc. now owns 10,227,201 shares of the conglomerate’s stock valued at $1,995,224,000 after buying an additional 30,658 shares during the period. Hedge funds and other institutional investors own 75.91% of the company’s stock.

Analyst Upgrades and Downgrades Several brokerages have weighed in on HON. Citigroup increased their target price on shares of Honeywell International from $260.00 to $279.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Bank of America upgraded shares of Honeywell International from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $205.00 to $265.00 in a report on Tuesday, July 28th. The Goldman Sachs Group boosted their target price on Honeywell International from $258.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Mizuho upped their price target on Honeywell International from $240.00 to $265.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. Finally, Royal Bank Of Canada dropped their price objective on Honeywell International from $298.00 to $293.00 and set an “outperform” rating for the company in a research note on Tuesday, August 18th. Thirteen research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $251.88.

Check Out Our Latest Research Report on Honeywell International

Insider Buying and Selling at Honeywell International In related news, CEO Kenneth West sold 17,032 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $243.77, for a total value of $4,151,890.64. Following the sale, the chief executive officer directly owned 2,132 shares of the company’s stock, valued at approximately $519,717.64. This trade represents a 88.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.15% of the stock is currently owned by insiders.

About Representative Hern Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

(Get Free Report)

Honeywell International Inc is a diversified technology and manufacturing company that develops products and systems for the aerospace, building automation, industrial automation, and energy markets. Its offerings include aircraft engines and auxiliary power units, avionics, flight-safety and control systems, building-management and security technologies, industrial control systems, sensors, software, and workplace safety products.

The company serves commercial and defense aerospace customers, building owners and operators, manufacturers, utilities, and other industrial businesses.

Featured Stories Five stocks we like better than Honeywell International Six Flags Launches FlexPay—Is There Any FUN Left in the Stock? Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around? Receive News & Ratings for Honeywell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Honeywell International and related companies with MarketBeat.com's FREE daily email newsletter.

Bullfrog AI (NASDAQ:BFRG – Get Free Report) and IQVIA (NYSE:IQV – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Profitability This table compares Bullfrog AI and IQVIA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Bullfrog AI N/A -150.36% -127.98% IQVIA 8.10% 30.25% 6.54% Volatility and Risk Bullfrog AI has a beta of -2.71, meaning that its share price is 371% less volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Earnings & Valuation This table compares Bullfrog AI and IQVIA”s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bullfrog AI $120,000.00 71.66 -$6.50 million ($0.46) -1.01 IQVIA $16.98 billion 2.58 $1.36 billion $8.06 33.09 IQVIA has higher revenue and earnings than Bullfrog AI. Bullfrog AI is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings This is a breakdown of recent ratings for Bullfrog AI and IQVIA, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 1 0 0 1.50 IQVIA 0 3 13 1 2.88 IQVIA has a consensus price target of $248.00, suggesting a potential downside of 7.01%. Given IQVIA’s stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Bullfrog AI.

Insider and Institutional Ownership 1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary IQVIA beats Bullfrog AI on 13 of the 15 factors compared between the two stocks.

About Bullfrog AI (Get Free Report)

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About IQVIA (Get Free Report)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.8% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, N.C., IQVIA Holdings Inc. provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Formed through the merger of IMS Health and Quintiles, the company helps clients develop and commercialize treatments using healthcare data, advanced analytics, technology and domain expertise. IQVIA operates in more than 100 countries and employs approximately 94,000 people.

IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. IQV has a Momentum Style Score of B, and shares are up 6.5% over the past four weeks.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $12.92 per share. IQV also boasts an average earnings surprise of +2.2%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IQV should be on investors' short list.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”). The proceeds from the Notes offering will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility and to pay fees and expenses relate.

IQVIA Holdings Inc. (“IQVIA”) NYSE:IQV today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2034 (the “Notes”).

The proceeds from the Notes offering will be used to redeem in full the Issuer’s Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering. The consummation of the Notes offering is subject to market and other customary conditions.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum.

About IQVIA

IQVIA NYSE:IQV is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

Forward Looking Statements

Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially.

IQVIAFIN

View source version on businesswire.com: https://www.businesswire.com/news/home/20260909467171/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced IQVIA Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors reduce avoidable delays and bring new therapies to patients up to two years faster. Traditional approaches in clinical development no longer keep pace with increasing trial complexity. IQVIA Predictive Clinical.

It has been about a month since the last earnings report for IQVIA Holdings (IQV - Free Report) . Shares have added about 5.6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for IQVIA Holdings Inc. before we dive into how investors and analysts have reacted as of late.

IQVIA Surpasses Q2 Earnings EstimatesIQVIA Holdings Inc. has reported second-quarter 2026 adjusted earnings of $3.15 per share, rising 12.1% year over year and beating the Zacks Consensus Estimate of $3.02 by 4.3%. Revenues of $4.36 billion increased 8.7% and topped the consensus mark of $4.29 billion by 1.6%.

The quarter benefited from broad-based segment growth and strengthening demand indicators. R&D Solutions generated record net new bookings of $3.15 billion, up 19% year over year, producing a 1.22X book-to-bill ratio.

IQV's Commercial Solutions Gains MomentumCommercial Solutions revenues were $1.79 billion, increasing 8.6% on a reported basis and 8.4% at constant currency. The business contributed roughly 41% to the total quarterly revenues.

Growth reflected double-digit gains in patient solutions and commercial engagement services. Analytics and consulting delivered high-single-digit organic growth, while increased adoption of IQVIA’s artificial intelligence solutions also contributed to the segment’s accelerating organic growth.

IQVIA's R&D Bookings Signal Strong DemandResearch & Development Solutions revenues reached $2.58 billion, up 8.8% as reported and 8.6% at constant currency. Excluding reimbursed expenses, revenues advanced 6.7% on a reported basis.

Demand indicators strengthened considerably. Trailing-12-month net new bookings rose 13% to $11.3 billion, while contracted backlog stood at $34.2 billion. IQVIA expects $9.2 billion of that backlog to convert into revenues over the next 12 months, representing 7.5% year-over-year growth.

The strong bookings performance provides improved visibility into future clinical research revenues. It also supports management’s expectation for sustained business momentum through the remainder of 2026 and into 2027.

IQV's Adjusted Profitability Holds FirmAdjusted EBITDA increased 9.2% year over year to $994 million. The adjusted EBITDA margin was 22.8%, modestly above the prior-year level, as profit growth slightly outpaced revenue growth.

Adjusted net income increased to $527 million from $486 million. The improvement reflected stronger operating performance despite higher stock-based compensation, restructuring-related expenses and acquisition-related costs included in the company’s reconciliation.

GAAP net income attributable to IQVIA was $256 million, down from $266 million a year earlier. GAAP diluted earnings were $1.53 per share compared with $1.54 in the prior-year quarter.

IQVIA's Operating Costs Reflect InvestmentCost of revenues increased to $2.93 billion from $2.69 billion in the year-ago quarter. Selling, general and administrative expenses rose to $574 million from $509 million, while depreciation and amortization increased to $292 million.

Restructuring costs nearly doubled to $63 million from $32 million. As a result, GAAP income from operations remained unchanged at $506 million despite the higher revenue base.

Interest expenses increased to $197 million from $182 million. These cost pressures explain the contrast between the decline in GAAP net income and stronger growth in adjusted earnings and EBITDA.

IQVIA's Cash Flow Supports Share RepurchasesThe second-quarter operating cash flow climbed 26% year over year to $558 million. The free cash flow rose 23.3% to $360 million after $198 million of property, equipment and software spending.

For the first half, the operating cash flow totaled $1.18 billion and the free cash flow reached $851 million. IQVIA repurchased $398 million of common stock during the quarter, bringing first-half repurchases to $950 million.

IQV's Balance Sheet Remains LeveragedIQVIA ended June with $1.91 billion in cash and cash equivalents, and $16 billion in debt. Net debt was $14.09 billion, while the net leverage ratio stood at 3.59X trailing-12-month adjusted EBITDA.

The company had $2.82 billion remaining under its share-repurchase authorization. Its current portion of long-term debt was $2.29 billion compared with $1.84 billion at the end of 2025.

IQV Raises Its 2026 Financial OutlookIQVIA raised its 2026 revenue guidance to $17.28-$17.48 billion from $17.15-$17.35 billion.

The updated forecast assumes 200 basis points of contribution from acquisitions, up from 150 basis points previously. It also incorporates a foreign-exchange tailwind of approximately 20 basis points, down from the prior assumption of 100 basis points.

Adjusted EBITDA guidance increased to $4-$4.05 billion from $3.98-$4.03 billion. IQVIA also lifted adjusted diluted earnings guidance to $12.80-$13 from $12.65-$12.95, reflecting stronger expected organic revenue growth and revised acquisition and currency impacts.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.

VGM ScoresAt this time, IQVIA has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, IQVIA has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerIQVIA is part of the Zacks Medical - Instruments industry. Over the past month, Edwards Lifesciences (EW - Free Report) , a stock from the same industry, has gained 5.9%. The company reported its results for the quarter ended June 2026 more than a month ago.

Edwards Lifesciences reported revenues of $1.74 billion in the last reported quarter, representing a year-over-year change of +13.6%. EPS of $0.78 for the same period compares with $0.67 a year ago.

For the current quarter, Edwards Lifesciences is expected to post earnings of $0.73 per share, indicating a change of +9% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

Edwards Lifesciences has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.

Callan Family Office LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,044 shares of the medical research company’s stock, valued at approximately $1,747,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter worth $2,811,292,000. Concurrent Investment Advisors LLC boosted its stake in shares of IQVIA by 36.0% during the 4th quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after purchasing an additional 3,161 shares in the last quarter. Focus Partners Advisor Solutions LLC purchased a new position in shares of IQVIA during the second quarter valued at about $976,000. Nippon Life Global Investors Americas Inc. raised its stake in IQVIA by 36.6% in the fourth quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock worth $17,898,000 after buying an additional 21,270 shares in the last quarter. Finally, Munich Reinsurance Co Stock Corp in Munich purchased a new stake in IQVIA in the fourth quarter worth about $3,444,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades Several research analysts have recently issued reports on IQV shares. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Mizuho raised their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Read Our Latest Stock Analysis on IQV Insider Buying and Selling In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock worth $3,098,793 in the last 90 days. 1.70% of the stock is owned by company insiders.

IQVIA Stock Performance Shares of IQV opened at $260.17 on Monday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $42.82 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.21 and a beta of 1.18. The business’s 50 day moving average price is $213.32 and its 200-day moving average price is $187.21. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $260.40.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the company earned $2.81 EPS. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has authorized a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

IQVIA Company Profile (Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

See Also Five stocks we like better than IQVIA VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing proble.

Bruni J V & Co. Co. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 66,918 shares of the medical research company’s stock, valued at approximately $12,929,896,000. IQVIA accounts for about 1.2% of Bruni J V & Co. Co.’s investment portfolio, making the stock its 26th largest position.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after buying an additional 159,899 shares during the period. BlackRock Inc. bought a new stake in IQVIA during the second quarter worth about $2,811,292,000. Geode Capital Management LLC grew its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners increased its stake in shares of IQVIA by 14.9% during the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after purchasing an additional 530,672 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 0.4% IQVIA stock opened at $240.25 on Wednesday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36. The business’s fifty day moving average is $208.88 and its 200 day moving average is $186.72. The stock has a market capitalization of $39.54 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year. IQVIA announced that its board has initiated a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Insider Activity at IQVIA In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last three months. 1.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In IQV has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price objective on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. Mizuho upped their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Stifel Nicolaus increased their price objective on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $241.88.

View Our Latest Stock Report on IQV

IQVIA Profile (Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Featured Stories Five stocks we like better than IQVIA The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways IQVIA shares gained 41.5% in three months, outpacing its industry and the S&P 500 Composite.R&DS net new bookings rose 19% to $3.2B, while contracted backlog reached $34.2B as of June 30, 2026.IQVIA raised its 2026 revenue and EPS guidance, while 1H share repurchases totaled $950M. IQVIA Holdings Inc. (IQV - Free Report) stock has rallied over the past three months. The company’s shares have jumped 41.5%, outperforming the industry’s 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick.

3-Month Share Price Performance                                                                 Image Source: Zacks Investment Research

Let us delve into the factors that have contributed to the company’s outperformance.

Record Net Bookings & Solid BacklogsIQVIA’s net new bookings were $3.2 billion for research and development solutions (R&DS) in the second quarter of 2026. It marked 19% year-over-year growth, resulting in a book-to-bill ratio of 1.22X. As the metric surpasses 1, it implies that new order intake exceeds current revenue recognition.

RD&S’s contracted backlog was $34.2 billion as of June 30, 2026. In the second quarter of 2026, the company anticipated $9.2 billion in backlog to convert to top line in the next 12 months, suggesting a 7.5% year-over-year increase.

A high backlog with substantial probability of future revenue provides analysts and investors long-term visibility into top-line growth, lowering earnings uncertainty. Highly predictable and recurring revenues raise investor confidence.

Raised 2026 Outlook Lifts Investor SentimentIn the second quarter of 2026, management uplifted revenue expectations to $17.28-$17.48 billion from the preceding quarter’s view of $17.15-$17.35 billion. The bottom-line prospect was raised to $12.8-$13 per share from $12.65-$12.95 provided during the first quarter of 2026.

A hike in top- and bottom-line guidance raises investors' confidence and prompts analysts to revise their financial models upward, resulting in higher price targets. Currently, based on short-term price targets provided by 19 analysts, the average price target for the stock is $265.26. It offers a 9.6% upside from the last closing price of $241.99.

                                                                 Image Source: Zacks Investment Research

Shareholder-Friendly ActionsIQVIA has demonstrated a strong commitment to returning value to its shareholders through an active share repurchase program. In 2025, IQV repurchased shares worth $1.24 billion. In the first half of 2026, the company’s share repurchases amounted to $950 million. This substantial buyback not only reduces the total outstanding share count, thereby increasing earnings per share, but also signals management's belief in the intrinsic value of the stock. 

Zacks Rank & Stocks to ConsiderIQVIA currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader Zacks Medical sector are Anika Therapeutics (ANIK - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , each flaunting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

ANIK has a long-term earnings growth expectation of 10%. Anika Therapeutics delivered a trailing four-quarter earnings surprise of 950%, on average.

BTSG has a long-term earnings growth expectation of 46%. BrightSpring delivered a trailing four-quarter earnings surprise of 16.1%, on average.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: IQVIA Holdings (IQV - Free Report) Headquartered in Durham, NC., IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in updated and innovative ideas in the process of clinical development and commercialization, speeding innovation and accelerating improvements. IQVIA Holdings operates in more than 100 countries, with around 88,000 employees.

IQV is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. IQV has a Momentum Style Score of B, and shares are up 11.2% over the past four weeks.

Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.12 to $12.92 per share. IQV also boasts an average earnings surprise of +2.2%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IQV should be on investors' short list.

Posted by Defense World Staff on Aug 5th, 2026

First Trust Advisors LP cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 55.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,023 shares of the medical research company’s  stock after selling 34,759 shares during the period. First Trust Advisors LP’s holdings in IQVIA were worth $4,779,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the 4th quarter valued at $25,000. Financial Freedom LLC bought a new position in IQVIA during the 1st quarter worth $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA during the first quarter worth $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter valued at about $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In Several analysts have weighed in on the stock. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. HSBC restated a “buy” rating and set a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. BMO Capital Markets lifted their price target on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. TD Cowen boosted their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada increased their price target on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Discover more

Self-Help & Motivational

Defense news subscription

Weapon system analysis

Firearms & Weapons

Defense World

Investing

View Our Latest Analysis on IQVIA

IQVIA Trading Down 2.2% Shares of IQVIA stock opened at $228.18 on Wednesday. The company has a market capitalization of $37.56 billion, a price-to-earnings ratio of 28.31, a PEG ratio of 1.97 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The firm’s 50-day moving average price is $197.37 and its two-hundred day moving average price is $186.67.

IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the previous year, the company earned $2.81 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.61 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases.  Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Insider Activity In other IQVIA  news, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction dated Monday, August 3rd. The  stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 in the last three months. Company insiders own 1.70% of the company’s stock.

Recent news headlines

About IQVIA (Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Featured Stories Five stocks we like better than IQVIA System Upgrade: First Internet Bancorp Options Surge AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push The AI Chip Blockade Is Creating a Shadow Market Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicrosoft Corporation $MSFT Shares Sold by Cantillon Capital Management LLC